Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Farmacia Hospitalaria
versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343
Resumen
MORENO-MARTINEZ, María Estela; VINENT-GENESTAR, Joan; MUNOZ-SANCHEZ, Carmen y CARRERAS-SOLER, María Josep. Hospital pharmacist's roles and responsibilities with CAR-T medicines. Farm Hosp. [online]. 2020, vol.44, n.1, pp.26-31. Epub 06-Jul-2020. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.11333.
The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain's hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist's role within the multidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients treated with this type of therapy, and emphasizing on the management of its main adverse effects. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the rest of the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity -and even improving previously established basic processes-.
Palabras clave : T-cell chimeric antigen receptor; Cytokine release syndrome; CAR-T-related encephalopathy syndrome; Pharmaceutical care.